innerbuddies gut microbiome testing

Gut Microbiome and Atherosclerotic Risk: Impacts on Heart Health

Your gut microbiome is more than a digestion partner—it’s an active regulator of cardiovascular risk. In people with higher atherosclerotic risk, gut microbes can shift the balance of beneficial and harmful species in ways that affect inflammation, cholesterol metabolism, and the health of blood vessel linings.

One key link is how the microbiome processes dietary components. Certain gut bacteria can transform nutrients into metabolites that influence atherosclerosis, including compounds related to bile acid signaling, oxidative stress, and inflammatory pathways. At the same time, microbial fermentation products (like short-chain fatty acids) may help support gut barrier integrity and dampen harmful immune activation—showing why microbial balance can either protect or predispose you to vascular disease.

The good news: your microbiome is modifiable. Diet patterns that promote a diverse, fiber-rich microbial ecosystem can encourage metabolite profiles associated with better vascular outcomes. By understanding the microbiome-to-heart mechanisms—especially inflammation, bile acid regulation, and diet-driven metabolite production—you can take targeted lifestyle steps that may help reduce atherosclerotic risk and support long-term heart health.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atherosclerotic risk

The article explains that the gut microbiome can influence atherosclerotic risk by shaping inflammation, lipid handling, and blood-vessel function. Key mechanisms include the TMA–TMAO pathway, where gut microbes convert dietary choline and carnitine to TMA that the liver oxidizes to TMAO, a molecule linked to plaque buildup and thrombosis; alterations in bile acid profiles also affect cholesterol metabolism and inflammatory signaling; and dietary fiber fermentation produces short-chain fatty acids like butyrate, propionate, and acetate that support gut barrier integrity and reduce inflammation. Because these pathways respond to diet and lifestyle, the microbiome is a modifiable target for lowering cardiovascular risk; emphasis is on a plant-forward, high-fiber pattern, unsaturated fats, and limited red meat/high-choline sources, plus regular activity, adequate sleep, and prudent antibiotic use.

Testing can reveal microbiome features associated with higher risk, such as reduced diversity and loss of beneficial taxa, and can identify functional patterns like TMAO production and SCFA output, which help explain lipid and inflammatory profiles. Common patterns include lower levels of taxa like Akkermansia and Faecalibacterium, and higher abundance of Enterobacteriaceae, Streptococcus, and other pro-inflammatory groups. While there is no single prevalence figure for 'microbiome-mediated' risk, these patterns are widespread in populations with cardiometabolic risk and typical Western diets; testing can guide personalized dietary and lifestyle adjustments to shift toward SCFA production and a healthier barrier.

InnerBuddies offers microbiome testing to assess these pathways and inform risk-focused nutrition planning, helping users understand whether their microbiome supports TMAO-related risk or protective outputs like SCFAs. The guidance emphasizes practical, dietary changes—diverse high-fiber plant foods, quality unsaturated fats, and reduced inputs that raise TMAO—along with exercise, sleep, and cautious antibiotic use. The evidence base is evolving, but consistent dietary patterns that bolster gut barrier and anti-inflammatory metabolism are presented as a practical approach to supporting heart health.

  • TMA/TMAO axis: Gut microbes convert dietary choline and carnitine into trimethylamine (TMA), which the liver oxidizes to TMAO; higher TMAO is linked to greater atherosclerotic burden and thrombotic risk.
  • SCFA production and barrier integrity: Loss of short-chain fatty acid (SCFA)–producing taxa (e.g., Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Butyrivibrio, Coprococcus) weakens gut barrier and promotes inflammatory signaling involved in atherosclerosis.
  • Bile acid remodeling: The microbiome alters bile acid profiles, which regulate cholesterol handling and inflammatory tone via receptors like FXR and TGR5, influencing lipid metabolism and vascular inflammation.
  • Gut barrier dysfunction and endotoxemia: Reduced microbial diversity with expansion of pro-inflammatory taxa (e.g., Enterobacteriaceae/Proteobacteria) can increase circulating endotoxins and chronic vascular inflammation.
  • Pro-atherogenic microbial patterns: Elevated taxa such as Enterobacteriaceae, Streptococcus, Bilophila wadsworthia, Ruminococcus gnavus group, Oscillibacter, and Alistipes correlate with inflammatory signaling and endothelial dysfunction.
  • Diet and lifestyle modulation: A plant-forward, high-fiber diet supports SCFA production and barrier integrity, while limiting red meat/high-choline sources may reduce TMAO-related risk; regular activity and adequate sleep further support a healthier gut–heart axis.
Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cardiovascular risk-related topics

Your gut microbiome—the community of microbes and their metabolic products in the digestive tract—can influence atherosclerotic risk by affecting inflammation, lipid metabolism, blood-vessel function, and the balance between pro- and anti-atherogenic signals. Differences in microbiome composition (often described as lower microbial diversity or reduced beneficial taxa) have been associated with a higher likelihood of developing cardiovascular disease. Mechanisms include changes in gut barrier integrity, which can allow microbial components to enter circulation and promote chronic, low-grade vascular inflammation.

Several microbiome-to-heart pathways are especially relevant to atherosclerosis. Microbial metabolism can generate or modulate compounds linked to cardiovascular risk, such as trimethylamine (TMA) and its liver-derived product trimethylamine N-oxide (TMAO), which have been associated with atherosclerosis and thrombotic risk in clinical and preclinical studies. Gut microbes can also shape bile acid profiles—key regulators of lipid absorption and signaling through receptors that affect cholesterol homeostasis and inflammation. Additionally, microbial fermentation of dietary fibers produces short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate, which generally support gut barrier function, help dampen inflammatory pathways, and may improve metabolic health.

Because these pathways are responsive to diet and lifestyle, the microbiome represents a modifiable target for reducing cardiovascular risk. Evidence-based lifestyle steps include increasing high-fiber, plant-forward foods (especially diverse fibers from legumes, vegetables, whole grains, and nuts), choosing unsaturated fats over highly processed diets, and limiting dietary patterns that increase TMAO-related substrates (commonly associated with higher intake of red meat and certain high-choline/high-carnitine dietary sources). Regular physical activity, adequate sleep, and avoiding unnecessary antibiotic exposure can also support a healthier microbial ecosystem. While microbiome tests and supplements are still an evolving area, consistent dietary patterns that foster SCFA production and a resilient gut barrier are a practical approach to supporting heart health.

  • Chest pain or pressure (angina) with exertion
  • Shortness of breath during physical activity
  • Fatigue or reduced exercise tolerance
  • Leg pain or cramping with walking (claudication)
  • Numbness, weakness, or sudden trouble speaking (possible TIA/stroke warning signs)
  • High blood pressure and/or worsening cholesterol results on lab tests
Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atherosclerotic risk

This information is most relevant for people concerned about atherosclerotic cardiovascular risk—such as those with high LDL, low HDL, hypertension, diabetes/prediabetes, a strong family history of heart disease, or other metabolic risk factors—because the gut microbiome can influence inflammation, lipid handling, and blood-vessel health. It’s also useful for anyone whose labs or clinical trajectory suggest worsening cardiovascular markers, even if symptoms are not yet severe.

It can be especially helpful if you experience symptoms that may be consistent with reduced blood flow to the heart or peripheral arteries, such as chest pressure/pain with exertion, shortness of breath during physical activity, fatigue or reduced exercise tolerance, or leg pain/cramping when walking (claudication). Since microbiome-related pathways (including chronic low-grade inflammation and altered lipid metabolism) may contribute to atherosclerosis progression, diet-driven gut support may be a complementary strategy alongside standard medical care.

This is relevant for people who suspect their lifestyle or diet may be promoting an “unfavorable” microbiome—often associated with lower diversity and fewer beneficial fiber-fermenting microbes—especially if their eating pattern is low in diverse plant fibers or high in highly processed foods and frequent red meat. It’s also appropriate for those interested in modifiable, practical approaches to gut health that support gut barrier integrity and favorable microbial metabolites (like SCFAs), with awareness that overuse of antibiotics and poor lifestyle factors can further disrupt the microbiome and potentially affect cardiovascular risk.

Atherosclerotic cardiovascular disease is extremely common in the adult population worldwide and is a major driver of heart attacks and strokes. While “gut microbiome–associated atherosclerotic risk” is not usually tracked as a standalone diagnosis with a single global prevalence number, population studies consistently show that many people—especially those with cardiometabolic risk factors—have gut microbiome patterns linked with higher inflammatory signaling and worse lipid/bile-acid metabolism, such as reduced microbial diversity and lower abundances of beneficial fiber-fermenting taxa. These microbiome features are widely prevalent across high-income and urbanized settings where diets tend to be lower in diverse plant fibers and higher in ultraprocessed foods and saturated fat.

From an outcomes perspective, atherosclerosis underlies a large fraction of cardiovascular events. In the United States, about 1 in 3 adults have some form of cardiovascular disease, and coronary artery disease affects tens of millions of people; in many Western countries, cardiovascular disease accounts for roughly one-quarter to one-third of all deaths. Common symptoms related to atherosclerosis—such as exertional chest pressure (angina), shortness of breath, fatigue/reduced exercise tolerance, claudication (leg pain with walking), and neurologic warning signs of TIA/stroke—reflect how broadly the condition manifests across the population once arterial disease develops.

Additionally, the “gut-to-heart” mechanisms described in the overview—such as microbiome-associated increases in TMA/TMAO, altered bile acid profiles, and reduced short-chain fatty acid (SCFA) production—are influenced by everyday dietary patterns that are highly prevalent. Diets that are low in diverse fiber and high in red/processed meat and other TMAO-related substrates are common in many populations, which helps explain why microbiome patterns associated with higher atherosclerotic risk are also common. As a result, even though no single percentage is assigned to “microbiome-mediated atherosclerotic risk,” the downstream clinical picture (high cholesterol, hypertension, and vascular events/symptoms) affects a substantial share of adults—often starting with risk-factor abnormalities before symptoms like angina, claudication, or stroke/TIA occur.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Atherosclerotic Risk: How Your Microbiome Impacts Heart Health

Atherosclerotic risk is increasingly linked to the gut microbiome because microbial composition and metabolic byproducts can influence inflammation, lipid handling, and blood-vessel health. When gut microbial diversity is lower or beneficial bacteria are reduced, the gut barrier may become less effective, allowing microbial components to enter circulation and drive chronic, low-grade vascular inflammation. Over time, this inflammatory environment can contribute to plaque formation and make cardiovascular symptoms—such as exertional chest discomfort, shortness of breath, or reduced exercise tolerance—more likely.

Several microbiome-driven pathways are particularly relevant to atherosclerosis. Gut microbes can convert dietary nutrients into trimethylamine (TMA), which the liver then transforms into trimethylamine N-oxide (TMAO); higher TMAO levels have been associated with increased atherosclerosis and thrombotic risk. The microbiome also helps shape bile acid profiles, which regulate cholesterol absorption and signal through receptors that affect lipid metabolism and inflammatory tone. In addition, microbial fermentation of dietary fiber produces short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate, which generally support gut barrier integrity and help dampen harmful inflammatory pathways.

Because these mechanisms are diet- and lifestyle-responsive, improving gut microbial function may help lower cardiovascular risk. Emphasizing a plant-forward pattern with diverse, high-fiber foods (legumes, vegetables, whole grains, and nuts) promotes SCFA production and a stronger gut barrier, while choosing unsaturated fats over highly processed diets supports healthier metabolic signaling. Limiting dietary patterns that can increase TMAO-related substrates—often associated with higher red meat intake and certain high-choline/high-carnitine sources—may also be beneficial. Along with regular physical activity, adequate sleep, and avoiding unnecessary antibiotics, these approaches can foster a more resilient microbiome, potentially lowering the likelihood of symptoms such as claudication from reduced blood flow or other warning signs related to vascular disease.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Atherosclerotic risk

  • Trimethylamine (TMA) → TMAO pathway: gut microbes convert dietary choline/carnitine into TMA, which the liver oxidizes to TMAO; higher TMAO is linked to greater atherosclerotic burden and thrombotic risk
  • Chronic low-grade inflammation via endotoxin/LPS translocation: reduced microbial diversity and weaker gut barrier (leaky gut) allow microbial components to enter circulation and trigger vascular inflammation
  • Bile acid remodeling and FXR/TGR5 signaling: gut microbiota alter bile acid composition, influencing cholesterol handling and modulating inflammatory tone through bile-acid–responsive receptors
  • Short-chain fatty acids (SCFAs) from fiber fermentation: beneficial bacteria generate butyrate/propionate/acetate that strengthen gut barrier function and can reduce pro-atherogenic inflammatory signaling
  • Dyslipidemia and altered lipid metabolism: microbiome-driven changes in metabolism (including effects on bile acids and SCFAs) can shift lipid profiles toward more atherogenic patterns
  • Prothrombotic/vascular dysfunction effects: microbial metabolites can influence platelet reactivity, endothelial function, and oxidative stress—factors that promote plaque progression and cardiovascular events

Atherosclerotic risk is increasingly tied to the gut microbiome through microbial metabolites that affect vascular biology. One key pathway is the trimethylamine (TMA) → TMAO route: gut bacteria break down dietary nutrients such as choline and carnitine into TMA, which the liver converts into trimethylamine N-oxide (TMAO). Higher circulating TMAO levels have been associated with greater atherosclerotic burden and increased thrombotic risk, linking everyday diet–microbe activity to plaque progression.

Beyond TMAO, gut microbial imbalance can promote chronic low-grade inflammation. When diversity is reduced and the intestinal barrier is weakened, bacterial components such as endotoxin/LPS can more easily enter circulation (often described as “leaky gut”). These inflammatory signals can heighten immune activation and worsen vascular inflammation, creating a biochemical environment that favors plaque formation and progression over time.

Gut microbes also influence cholesterol handling and inflammatory tone by remodeling bile acids and generating short-chain fatty acids (SCFAs). Microbial changes in bile acid profiles affect receptors involved in lipid metabolism and immune signaling (including FXR and TGR5 pathways). Meanwhile, fermentation of dietary fiber produces SCFAs like butyrate, propionate, and acetate, which tend to support gut barrier integrity and help reduce pro-atherogenic inflammatory signaling. Together, these microbiome-driven effects can contribute to dyslipidemia, impaired endothelial function, and a more prothrombotic state—mechanisms that collectively increase cardiovascular risk.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In individuals with higher atherosclerotic risk, gut microbial patterns often show reduced diversity and a shift away from taxa that support gut barrier function and anti-inflammatory metabolism. When beneficial communities are diminished, the intestinal lining can become more vulnerable to damage, which may allow microbial components and inflammatory signals to cross into circulation more easily. This tendency toward chronic low-grade immune activation can promote vascular inflammation and help create conditions that favor plaque initiation and progression.

A common microbiome-associated mechanism involves altered nutrient fermentation that increases production of trimethylamine (TMA), a compound derived from dietary precursors such as choline and carnitine. Certain gut microbial communities are better at generating TMA, and the liver converts it to trimethylamine N-oxide (TMAO), which has been linked in many studies to greater atherosclerotic burden and higher thrombotic risk. In parallel, disruptions in normal bile acid processing can further influence lipid handling and inflammatory signaling, because bile acid profiles are tightly shaped by the microbiome and act through host receptors that modulate metabolism and vascular immune responses.

Another recurring pattern is a lower capacity to generate short-chain fatty acids (SCFAs)—including butyrate, propionate, and acetate—typically supported by diets rich in diverse, fermentable fiber. When SCFA-producing pathways are weakened, the gut barrier may be less resilient and inflammatory tone may rise, partly through reduced signaling that normally supports metabolic health and immune regulation. Together, diminished SCFA production, more pro-inflammatory microbial signaling, and increased TMAO-related metabolism can contribute to endothelial dysfunction, dysregulated lipid metabolism, and a more pro-atherogenic, prothrombotic milieu.


Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Butyrivibrio spp.
  • Coprococcus spp.
  • Eubacterium rectale
  • Bifidobacterium longum
  • Bifidobacterium adolescentis
  • Anaerostipes spp.
  • Christensenellaceae (genus incertae sedis; e.g., Christensenellaceae taxa)


Elevated / overrepresented taxa

  • Enterobacteriaceae (family; e.g., Escherichia/Shigella)
  • Streptococcus (genus)
  • Proteobacteria (phylum-level increase)
  • Bacteroides (genus; relative shift in bile-tolerant profiles)
  • Alistipes (genus)
  • Ruminococcus gnavus group (species-group; e.g., R. gnavus complex)
  • Oscillibacter (genus)
  • Bilophila wadsworthia (genus)


Functional pathways involved

  • Microbial trimethylamine (TMA) generation from choline/carnitine (TMA-producing fermentation pathways)
  • TMAO-associated microbial metabolism and hepatic conversion via host flavin-containing monooxygenase (FMO3-linked TMAO axis)
  • Short-chain fatty acid (SCFA) biosynthesis from fermentable fibers (butyrate/propionate/acetate production pathways)
  • Intestinal epithelial barrier integrity and mucus-related metabolism (including mucin utilization/supply and barrier-supporting metabolite synthesis)
  • Bile acid transformation pathways (secondary bile acid formation and bile acid deconjugation via microbiome)
  • Lipopolysaccharide (LPS) / endotoxin-related inflammatory signaling potential (Gram-negative outer membrane components signaling pathways)
  • Bacterial carbohydrate and protein fermentation shifts (rebalancing of fermentable substrates that influence inflammation and metabolite profiles)
  • Microbial N- and nitrogen metabolism influencing oxidative stress and immune activation (e.g., polyamine/amino-acid derived pro-inflammatory signaling potential)


Diversity note

In people with higher atherosclerotic risk, gut microbiome studies commonly show reduced overall microbial diversity along with a shift away from taxa that help maintain intestinal barrier integrity and produce anti-inflammatory metabolites. When beneficial microbial communities are depleted, the gut lining can become more susceptible to damage, which may allow microbial fragments and inflammatory signals to reach the bloodstream more easily and sustain chronic, low-grade vascular inflammation—an important driver of plaque development.

This loss of diversity is often accompanied by functional changes in how the microbiome processes nutrients. For example, a microbiome that is less balanced may increase capacity for generating trimethylamine (TMA) from dietary precursors such as choline and carnitine, which the liver converts into trimethylamine N-oxide (TMAO). At the same time, altered microbial bile acid metabolism can affect cholesterol handling and inflammatory signaling through host receptors that regulate metabolic and immune pathways.

Another frequent pattern is diminished generation of short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate—metabolites largely supported by diverse, fermentable fiber intake. Lower SCFA output can weaken gut barrier resilience and reduce signaling that normally tempers immune activation. Together, reduced diversity with fewer barrier-protective and SCFA-producing microbes may help create an environment that promotes endothelial dysfunction, unfavorable lipid metabolism, and a more pro-atherogenic inflammatory state.


Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic “heart-healthy” advice often fails for atherosclerotic risk because it targets traditional risk factors (e.g., cholesterol numbers or general diet quality) without addressing the specific gut-microbiome processes that can drive chronic vascular inflammation. Many people follow broad recommendations but don’t change the microbial ecology enough to restore diversity, strengthen the gut barrier, or rebalance microbial metabolic outputs—meaning harmful signals can continue to reach the circulation even when overall diet seems “healthy.” As a result, endothelial dysfunction and low-grade immune activation may persist, limiting the clinical impact of generic interventions.

    Another reason broad solutions underperform is that the microbiome’s contribution to atherosclerosis depends on downstream metabolites rather than single nutrients. For example, simply reducing saturated fat or “eating less red meat” doesn’t necessarily lower the gut microbial capacity to generate TMA (and therefore TMAO), because TMAO-related pathways also depend on an individual’s baseline microbial taxa, fermentation patterns, and the types of substrates present in the diet. Similarly, bile acid signaling—shaped by the microbiome—may not shift meaningfully with generic dietary changes, so cholesterol handling and inflammatory tone can remain relatively unchanged.

    Finally, many approaches fail because they overlook that beneficial effects usually require microbiome-supportive inputs over time, not one-off modifications. Generic plans may not reliably increase fermentable, diverse fibers that support short-chain fatty acid (SCFA) production (e.g., butyrate, propionate, acetate), which are commonly linked to gut barrier integrity and anti-inflammatory signaling. Without sufficient and sustained shifts toward fiber diversity, unsaturated fats in the right food matrix, and lifestyle factors that preserve microbial resilience, the gut barrier may remain more permeable and pro-inflammatory microbial signaling may continue to promote plaque initiation and progression.

  • Common mistakes

    • Focusing only on traditional targets (LDL/“heart-healthy” diet) while ignoring gut-microbiome-driven metabolites (e.g., TMA/TMAO, SCFAs, bile-acid signaling) that more directly reflect microbial functional capacity.
    • Assuming that cutting a single food or nutrient (e.g., less red meat, less choline/carnitine, less saturated fat) will reliably reduce TMAO—without addressing the baseline gut taxa and fermentation pathways that determine TMA production.
    • Not increasing fermentable fiber diversity enough to restore SCFA-generating capacity (butyrate/propionate/acetate), which limits gut barrier reinforcement and anti-inflammatory signaling.
    • Using “whole grains/veg” advice that improves overall diet quality but fails to change microbial ecology meaningfully (insufficient fiber variety, low total fermentable substrate, or rapid reversion after the intervention).
    • Overlooking bile acid–microbiome interactions: making diet changes that don’t shift bile acid composition or host receptor signaling (e.g., FXR/TGR5 pathways) that influence lipid handling and vascular inflammation.
    • Trying short-term or one-size-fits-all protocols; beneficial microbiome effects typically require sustained, ecology-supportive inputs over weeks to months to years.
    • Neglecting individual variation (baseline microbiome, antibiotic history, constipation patterns, microbiome-related metabolic differences), leading to interventions that don’t fit the person’s dominant microbial functions.
    • Over-relying on supplements or probiotics without matching them to diet-driven substrate availability—so introduced strains/features can’t persist or meaningfully alter metabolite outputs (TMAO/SCFAs/bile acids).

What to do

  • General support strategies

    Gut microbiome–focused strategies for atherosclerotic risk center on strengthening the gut barrier, reducing low-grade inflammation, and improving how the body handles lipids and bile acids. When microbial diversity declines or beneficial species decrease, the gut lining can become more permeable, allowing inflammatory microbial signals to circulate and promote vascular dysfunction. Supporting a resilient microbiome with a plant-forward, fiber-rich eating pattern helps encourage short-chain fatty acid (SCFA) production (such as butyrate and propionate), which is associated with better barrier integrity and a calmer inflammatory tone.

    Diet can also influence TMAO, a gut-microbe–derived metabolite linked in studies to higher atherosclerosis and thrombotic risk. Strategies that emphasize minimally processed foods and reduce reliance on dietary patterns that are higher in red meat and certain choline-rich animal sources may lower TMAO-related substrate availability. At the same time, prioritizing unsaturated fats (from olive oil, nuts, seeds, and fatty fish if desired) and maintaining adequate fiber supports healthier bile acid profiles, which regulate cholesterol absorption and affect metabolic and immune signaling.

    Lifestyle and medication considerations can further reinforce these gut–vascular pathways. Regular physical activity and good sleep help maintain microbial diversity and metabolic balance, while unnecessary antibiotic exposure can disrupt beneficial communities and should be avoided when possible. Consistently consuming a diverse range of whole plant foods—legumes, vegetables, whole grains, nuts, and seeds—provides the fermentable substrates that encourage beneficial bacteria, supporting long-term cardiovascular-friendly gut function and potentially lowering the likelihood of symptoms related to worsening vascular health.

  • Lifestyle recommendations

    • Follow a plant-forward, high-fiber eating pattern (legumes, vegetables, whole grains, nuts) to support beneficial gut bacteria and increase SCFA production.
    • Choose unsaturated fats (olive oil, nuts, seeds, fatty fish) and limit highly processed foods to improve metabolic and inflammatory signaling relevant to vascular health.
    • Reduce foods and patterns associated with higher TMAO risk (e.g., limit red meat and high-choline/high-carnitine processed animal products).
    • Maintain regular physical activity to support vascular function and healthier gut–metabolism pathways.
    • Prioritize sleep and stress management, as chronic stress and poor sleep can worsen gut barrier integrity and inflammation.
    • Use antibiotics only when truly needed and discuss alternatives with a clinician to avoid unnecessary microbiome disruption.

  • Nutrition recommendations

    • Eat a plant-forward, high-fiber diet (e.g., legumes, vegetables, whole grains, nuts, seeds) to support SCFA production (butyrate/propionate/acetate) and improve gut barrier integrity—helpful for lowering low-grade vascular inflammation.
    • Prioritize unsaturated fats over highly processed fats by choosing olive oil, nuts, seeds, and fatty fish; limit fried and ultra-processed foods that can worsen metabolic and inflammatory signaling.
    • Reduce intake of TMAO-promoting foods by moderating red meat and avoiding frequent high-carnitine/high-choline processed animal products; when you eat meat, keep portions moderate and balance with fiber-rich plant foods.
    • Include microbiome-friendly prebiotics such as onions, garlic (including cooked), leeks, asparagus, bananas (slightly green if tolerated), oats, and legumes to feed beneficial bacteria.
    • Aim for diverse weekly plants (a “variety” approach) to increase microbial diversity; rotate fiber sources rather than relying on a single staple.
    • Consider fermented foods (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi) if you tolerate them, to support beneficial strains that may help modulate inflammation and bile acid metabolism.

  • Supplement considerations

    For atherosclerotic risk, gut-targeted supplements are often considered to support microbial diversity, strengthen the intestinal barrier, and reduce low-grade inflammation that can contribute to plaque development. In particular, probiotics (and sometimes synbiotics) may be used to help shift the microbiome toward more beneficial, fiber-fermenting profiles, which can support gut tight-junction integrity and reduce inflammatory signaling. Because individual responses vary widely by baseline diet and microbiome composition, choosing evidence-backed strains (or tailored synbiotic blends that include complementary prebiotic fibers) may be more practical than relying on high-dose, single-strain products without clear strain identity.

    Another major supplement consideration involves reducing microbiome-driven generation of TMAO, a compound linked in many studies to higher atherosclerotic and thrombotic risk. Nutrients and compounds that increase substrates for TMA production (commonly from certain dietary patterns high in red meat or high in specific choline/carnitine sources) are typically addressed first through diet, but supplement strategies can also include approaches that promote a more favorable microbial metabolism. Some practitioners consider prebiotics or dietary-fiber–derived supplements (like inulin, resistant starch, or partially hydrolyzed fibers) to boost SCFA production (including butyrate and propionate), which generally supports barrier function and may indirectly counter pro-atherogenic inflammatory pathways.

    Finally, supplementation decisions for cardiovascular outcomes should be integrated with proven lifestyle pillars—especially fiber-rich, plant-forward eating and regular activity—since the gut microbiome is highly responsive to diet. If considering supplements, it’s also important to watch for interactions and contraindications (for example, probiotics in immunocompromised individuals), to avoid unnecessary antibiotic exposure, and to align any gut-directed plan with standard cardiovascular risk management (lipid control, blood pressure management, and smoking cessation). When possible, selecting products with transparent strain characterization, quality testing, and clinically relevant dosing can improve the likelihood of benefit while reducing uncertainty.

  • Retesting / monitoring note

    For individuals addressing atherosclerotic risk through a gut-microbiome lens, retesting is typically considered after a meaningful period of lifestyle or nutrition change—often around 8–12 weeks—to allow gut community and metabolic outputs to shift. If the initial assessment suggested low microbial diversity, reduced abundance of beneficial, fiber-fermenting taxa, or patterns linked with higher TMAO-related activity, a follow-up can help determine whether diet adjustments (e.g., increasing legumes, vegetables, whole grains, and nuts) are translating into more favorable microbial functions and metabolite profiles.

    Retesting is also useful when there are ongoing symptoms or changes in cardiovascular risk factors, such as new exertional chest discomfort, shortness of breath, or worsening exercise tolerance, because gut-driven inflammation can evolve alongside systemic health. In these cases, follow-up timing may be guided by how quickly other clinical factors are being optimized (for example, cholesterol management, blood pressure control, and physical activity), with retesting commonly aligned to 3–6 month intervals when broader metabolic stabilization is expected.

    Finally, repeat testing may be considered if antibiotics, major dietary disruptions, gastrointestinal infections, or significant medication changes occur, since these can temporarily alter microbial composition and bile acid/SCFA production. To improve interpretability, retesting should use consistent sample collection and test methodology, and ideally pair microbiome results with standard cardiovascular biomarkers and clinician-led risk assessment—so microbiome changes can be contextualized within overall vascular risk management.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for assessing atherosclerotic risk because it can reveal how your intestinal ecosystem may be influencing inflammation, lipid handling, and blood-vessel function. When microbial diversity is lower or beneficial taxa are reduced, the gut barrier can become more permeable, allowing inflammatory microbial components to reach circulation and support chronic, low-grade vascular inflammation—an important driver of plaque formation and cardiovascular symptoms.

    Testing is also useful because specific microbial metabolic pathways can shift risk markers tied to atherosclerosis. For example, some gut microbes convert dietary nutrients into trimethylamine (TMA), which the liver turns into TMAO; elevated TMAO levels have been associated with higher atherosclerotic and thrombotic risk. Microbiome profiles can also indicate how bile acids are being modified, which affects cholesterol absorption and signaling through receptors that influence both lipid metabolism and inflammatory tone.

    Finally, microbiome testing helps identify whether your current diet and lifestyle are supporting protective outputs like short-chain fatty acids (SCFAs) from fiber fermentation (e.g., butyrate, propionate, and acetate). If testing suggests weaker SCFA-supporting communities or gut-barrier–related imbalances, you and your clinician can tailor interventions—such as increasing diverse, high-fiber plant foods, optimizing fat quality, and reducing inputs linked with TMAO production—to potentially improve vascular risk over time.

  • How InnerBuddies helps

    InnerBuddies can help with an atherosclerotic risk indication by giving you insight into your gut microbiome’s potential to influence inflammation, lipid handling, and vascular health. Because microbial community structure and activity affect how well your gut barrier functions, the test can provide clues about whether your current ecosystem is supporting a resilient intestinal lining or, instead, leaning toward a pattern associated with more “leaky gut” physiology and chronic, low-grade inflammatory signaling that contributes to plaque formation.

    The test may also be informative for pathways linked to cardiovascular risk, particularly those involving microbial metabolites. For example, gut microbes can generate trimethylamine (TMA), which the liver converts into TMAO—an end product associated with higher atherosclerosis and thrombotic risk in clinical studies. By characterizing your microbial profile, InnerBuddies can help suggest whether your community is more likely to support TMA-generating activity versus patterns that are generally more protective for metabolic and inflammatory balance.

    Finally, InnerBuddies can support risk-focused nutrition planning by reflecting how your microbiome may respond to dietary inputs that drive beneficial outputs such as short-chain fatty acids (SCFAs) from fiber fermentation (including butyrate, propionate, and acetate). Since SCFAs are tied to gut barrier integrity and reduced harmful inflammatory pathways, the results can help guide practical diet and lifestyle adjustments—like increasing diverse, high-fiber plant foods and optimizing fat quality—to promote a microbiome that may better support cardiovascular health over time.

Medical Evidence

  • Scientific evidence level

    3 [moderate: multiple plausible links and consistent associations, but causality and intervention/clinical utility remain insufficient and inconsistent]

  • Clinical relevance note

    At present, the gut microbiome can be considered a biologically plausible contributor to atherosclerotic processes—particularly through metabolite pathways (e.g., TMA/TMAO) and immune/metabolic signaling. However, translating this into clinical practice for “atherosclerotic risk” is not yet supported by high-quality evidence. Most human studies are observational with moderate effect sizes, substantial confounding potential (diet and medications), and frequent issues of reproducibility (methodological heterogeneity, batch effects, and variable pipelines).

    Clinical relevance is therefore limited: measuring the gut microbiome is not validated for routine ASCVD risk prediction, and microbiome-targeted interventions have not convincingly demonstrated reductions in clinical atherosclerotic endpoints in adequately powered, standardized RCTs. Some interventions may modulate metabolites or inflammatory markers, but “actionable intervention evidence” is not equivalent to “validated clinical application.” The strongest current use of this field is hypothesis generation and risk biology rather than decision-making—until larger, well-controlled longitudinal cohorts, standardized microbiome/metabolomics methods, and definitive clinical trials link microbiome modulation to plaque progression or cardiovascular event reduction.

Title Journal Year Link
Distinct gut microbiomes have been associated with atherosclerotic risk and cardiovascular disease Nature 2019 View →
The gut microbiome regulates the balance between Th17 and regulatory T cells and the development of atherosclerosis Nature Communications 2019 View →
Plasma TMAO levels predict mortality in patients with acute coronary syndrome Journal of the American College of Cardiology 2015 View →
Gut microbial metabolism of trimethylamine N-oxide (TMAO) and atherosclerosis The New England Journal of Medicine 2013 View →
A gut microbiota-dependent mechanism for lipopolysaccharide-induced insulin resistance, inflammation, and atherosclerosis Proceedings of the National Academy of Sciences (PNAS) 2012 View →

Frequently Asked Questions

    Qu'est‑ce que le microbiote intestinal et comment influène‑t‑il le risque d’athérosclérose ?
    Le microbiote intestinal est la communauté de microbes du tube digestif; leurs métabolites peuvent influencer l'inflammation, le métabolisme des lipides et la fonction vasculaire, ce qui peut modifier le risque cardiovasculaire. Le régime et le mode de vie peuvent le moduler.
    Qu’est‑ce que le TMAO et pourquoi est‑il lié à l’athérosclérose et au risque thrombotique ?
    Le TMAO se forme lorsque les microbes intestinaux dégradent des nutriments comme la choline et la carnitine; le foie le convertit en TMAO. Des niveaux plus élevés ont été associés à une charge athérosclérosique accrue et à un risque thrombotique. Ce n’est pas un diagnostic.
    Comment réduire le risque cardiovasculaire lié au microbiome par l’alimentation ?
    Mettre l’accent sur une alimentation diversifiée riche en fibres végétales; privilégier les graisses insaturées; limiter la viande rouge et les aliments riches en choline/carnitine; rester actif, dormir suffisamment, éviter les antibiotiques inutiles.
    Quels aliments favorisent les bactéries intestinales bénéfiques pour le cœur ?
    Légumineuses, légumes, céréales complètes, noix; fibres variées; huile d’olive, poissons gras; limiter les aliments ultra-transformés.
    Les tests du microbiome permettent‑ils de renseigner de façon fiable sur le risque cardiovasculaire ?
    Ils donnent des informations sur l’écosystème intestinal et les voies métaboliques, mais ne remplacent pas un diagnostic. Interprétez-les avec un professionnel et en complément des facteurs de risque établis.
    Quelles habitudes de vie, au‑delà de l’alimentation, soutiennent un microbiome et un cœur plus sains ?
    Activité physique régulière, sommeil suffisant, gestion du stress, utilisation limitée des antibiotiques, hydratation.
    Quelles bactéries intestinales sont considérées comme bénéfiques pour la santé cardiovasculaire ?
    Des genres comme Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia, Butyrivibrio, Coprococcus, Eubacterium rectale, Bifidobacterium et Christensenellaceae sont souvent cités comme bénéfiques.
    Quelles bactéries sont souvent associées à un risque plus élevé et dois‑je m’en inquiéter ?
    Des taxa élevés incluent Enterobacteriaceae, Streptococcus, Proteobacteria, Bacteroides, Alistipes, groupe Ruminococcus gnavus, Oscillibacter, Bilophila wadsworthia. L’interprétation doit se faire avec un médecin.
    Comment l’intégrité de la barrière intestinale influence l’inflammation et le risque cardio-vasculaire ?
    Une barrière plus perméable peut laisser passer des composants microbiens dans la circulation, favorisant une inflammation chronique associée à des maladies vasculaires. Le régime et le mode de vie peuvent soutenir l’intégrité de la barrière.
    Comment les acides biliaires interagissent‑ils avec le microbiome et le métabolisme du cholestérol ?
    Le microbiome façonne les profils d’acides biliaires, qui influencent l’absorption du cholestérol et la signalisation par des récepteurs régulant le métabolisme et l’inflammation.
    Qu’est-ce que les acides gras à chaîne courte (SCFA) et pourquoi sont‑ils importants pour le cœur ?
    Les SCFA comme le butyrate, le propionate et l’acétate proviennent de la fermentation des fibres; ils soutiennent la barrière intestinale et réduisent les signaux inflammatoires nuisibles, soutenant la santé métabolique.
    En combien de temps les changements alimentaires peuvent‑ils modifier le microbiome et potentiellement le risque ?
    Le microbiome peut réagir en quelques semaines; des modifications du risque nécessitent du temps et dépendent de nombreux facteurs. Visez des habitudes durables.
    Existe‑t‑il des preuves que l’exercice améliore les bénéfices du microbiome pour le cœur ?
    L’exercice régulier tend à favoriser un microbiome plus sain et à réduire le risque vasculaire; les résultats varient, mais l’activité physique est recommandée.
    Y a‑t‑il des risques liés aux tests du microbiome ou aux compléments ?
    Les tests sont exploratoires et ne remplacent pas les soins médicaux. Discutez des compléments avec votre médecin et évitez les antibiotiques inutiles.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -